LONDON, UNITED KINGDOM--(Marketwired - Mar 30, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of biopharmaceutical products including the highly bioavailable Phytofare® catechin complex, today announced that it has signed a distribution agreement with California-based AIDP Inc. that will enable them to offer Phytofare® to their established customer base throughout the world. This agreement will create a way for the company to sell to a wider clientele, including the United States, whereas existing distribution has focused primarily on Europe and Africa.

AIDP Inc. has over 20 years' experience as a leader in functional ingredients with a focus on extensively researched products in the functional food, nutritional and beverage product development industries. They market and distribute a variety of branded ingredients and over 200 commodity ingredients for numerous health conditions including cognitive, digestive and bone health, providing cutting edge solutions that meet consumer demand for wellness and healthy aging.

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, commented, "We could not be more pleased to align Phytofare® with a distributor having the stature and reputation of AIDP. They are known for sourcing high-quality ingredients and providing proprietary solutions that address formulation challenges the health and wellness industries. Phytofare®, and its encapsulated sister product, ph2 TM, fit nicely with their product range and existing customer base. This relationship, which covers everywhere except Europe and Africa where we are already strongly represented, gives us immediate worldwide exposure and distribution. We look forward to a long and mutually profitable partnership."

Alan Rillorta, Director of Protein and Branded Ingredients at AIDP, added, "With Phytofare®, we are adding to our full range of solutions for functional food and beverage producers. Plandaí's proprietary technology provides scientific proof that the form of Green Tea really does matter, with Phytofare® providing significant advantages over generic and other green tea products currently available on the market."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop biopharmaceutical products demonstrating high levels of phyto-availability™. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information:

Hannah Merrill